P302 Cytomegalovirus infection in pediatric acute severe ulcerative colitis – a multicenter case-controlled study from the Pediatric IBD Porto group of ESPGHAN
Cohen S.*1, Martinez-Vinson C.2, Aloi M.3, Turner D.4, Assa A.5, de Ridder L.6, Wolters V.M.7, de Meij T.8, Alvisi P.9, Bronsky J.10, Kopylov U.11
1“Dana-Dwek” Children's Hospital, Tel Aviv Sourasky Medical Center, The Pediatric Gastroenterology unit, Tel Aviv, Israel 2Hopital Robert Debré, Department of Gastroenterology and Nutrition, Paris, France 3Sapienza University of Rome, Pediatric Gastroenterology and liver unit, Rome, Italy 4Shaare Zedek Medical Center, Department of Paediatric Gastroenterology, Jerusalem, Israel 5Schneider Children's Medical Center, Department of Gastroenterology, Nutrition and Liver Diseases, Petach Tikvah, Israel 6Children's Hospital Erasmus MC Sophia, Department of Paediatric Gastroenterology, Rotterdam, Netherlands 7University Medical Center Utrecht, Department of Gastroenterology, Utrecht, Netherlands 8Vrije Universiteit Medical Center, Pediatric Gastroenterology, Amsterdam, Netherlands 9'Maggiore Hospital', GI Unit, Bologna, Italy 10University Hospital Motol, Department of Paediatrics, Prague 5, Czech Republic 11Sheba Medical Center, Department of Gastroenterology and Liver Diseases, Ramat Gan, Israel
Data on the clinical course and outcomes of pediatric patients with cytomegalovirus (CMV) infection complicating acute severe ulcerative colitis (ASC) is very limited. The aim of our study was to compare the outcome of CMV-positive and negative pediatric ASC.
This was a multicenter retrospective case-controlled study, from centers in Europe and Israel. We included CMV-positive pediatric patients hospitalized for acute severe colitis and compared their outcomes (rate of colectomy during hospitalization and up to 1 year from the hospitalization) to matched CMV-negative controls
A total of 56 children from 10 centers were included. The patient cohort included 23 (41.1%) males/ 33 (58.9%) females, with a median age of 11.5 (interquartile range (IQR) – 7–14) years. Fifty-two (92.9%) of the patients had extensive/pan-colitis colitis and the rest left sided colitis, with severe disease in 52 (92.9%) of the patients and moderate in 4 (7.1%). Fifteen patients were CMV-positive and 41 – CMV-negative. Significantly higher proportion of CMV positive patients were resistant to intravenous corticosteroids (p=0.009). After diagnosis of CMV infection, 14/15 patients were started on gancyclovir (5 mg/kg – 5/14 (35.7%) and 10 mg/kg – 9/14 (64.3%). During hospitalization, 3 (20%) CMV positive and 3 (7.8%) CMV-negative patients required colectomy (p=0.17). By 12 months of follow-up, 5 (33.3%) and 5 (12.5%) CMV positive and negative patients required colectomy, respectively (p=0.049). Previous anti-TNF exposure and Pediatric Ulcerative Colitis Activity Index score on index date were significantly associated with the risk of colectomy during hospitalization and by 12 months (p=0.037 and p=0.01 for previous anti-TNF exposure and p=0.021 for PUCAI) on univariate analysis, however none of the factors including CMV positivity retained significance on multivariate analysis.
A higher prevalence of CMV positivity was found in pediatric UC patients who required colectomy within 12 months of index hospitalisation, however the difference was not statistically significant on multivariate analysis. Further studies are merited to clarify the impact of CMV infection on the outcome of acute severe colitis in pediatric patients